Angelalign Technology's ROCE trend is uninspiring. Despite reinvestment for growth, sales remain stagnant. The stock has dropped 43% in a year, making investors wary. It doesn't seem to have multi-bagger potential.
Despite Angelalign Technology's lower-than-average ROE compared to the industry standard of 10%, its impressive earnings growth rate indicates that the company's management may have made strategic decisions that effectively utilize its profits.
時代天使股票討論區
主要摘要:
1.預計中國隱形矯正行業長期病例數量的 CAGR 將會增加...
暫無評論